California Tuberculosis Prevention and Control Objectives and Targets 2024-2029, by Strategy Areaā
Objectives in regular font are NTIP indicators. Objectives in italics are California (non-NTIP) indicators
California Targets
| Objāectiveā | 2025āā | 2026 | 2027ā | 2028ā | 2029ā |
Strategy 1: Diagnosis and treatment of persons with TB disease
1.1a TB Case Rate
| 4.7
| 4.3
| 3.9
| 3.6 | 3.2 |
1.1b US-Born Case Rateā
| 1.0
| 0.9
| 0.7
| 0.6
| 0.5
|
1.1c Non US-Born Case Rate
| 15.1
| 14.4 | 13.6
| 12.8 | 12.0 |
1.1d African American Case Rate
| 1.6
| 1.2 | 0.āā8 | 0.5 | 0.1 |
1.1e Pediatric Case Rate
| 0.9
| 0.7
| 0.5 | 0.3 | 0.1 |
1.1f Asian Case Rate | 15.9 | 15.4 | 14.8 | 14.3 | 13.7 |
1.1g Hispanic/Latinx Case Rate | 4.5 | 4.1 | 3.7 | 3.2 | 2.8 |
1.2 Known HIV Status | 92% | 94% | 95%
| 97% | 98% |
1.3 Drug Susceptibility Result
| 96% | 96% | 97% | 98% | 98% |
1.4 Sputum Culture Reported | 93%
| 94% | 95% | 95% | 96% |
1.5 āRecommended Initial Therapy | 94%
| 94% | 95% | 96% | 97% |
1.6 Treatment Initiation
| 91% | 92%
| 93% | 94% | 94% |
1.7 Sputum Culture Conversion | 75% | 76% | 77% | 78% | 79% |
1.8 Completion of Therapy | 89% | 89% | 90% | 90% | 91% |
1.9a Nucleic Acid Amplification Test Used ā Smear-Positive TB | 73% | 76% | 80% | 84% | 88% |
1.9b Nucleic Acid Amplification Test Used ā Smear-Negative TB | 47% | 51% | 54% | 58% | 61% |
1.10 Self-Administered Therapy | 1.3% | 1.2% | 1.2% | 1.1% | 1.1% |
1.11 Deaths with TB | 8.9% | 8.0% | 7.1% | 6.2% | 5.3% |
Strategy 2: Conduct contact investigationās fāor infectious TB cases
2.1 Contact Elicitation*
| 92%āāā
| 94%ā
| 95%
| 97%
| 98%
|
2.2 Contact Examination*
| 82% | 83%
| 84% | 86% | 87% |
2.3 Contact LTBI Treatment Initiation*
| 78%
| 80%
| 82% | 85% | 87% |
2.4 Contact LTBI Treatment Completion (of those starting treatment)*
| 82%
| 85%
| 87%
| 90%
| 93%
|
2.4a Contact LTBI Treatment Completion (of those with LTBI)** | 65% | 69% | 74%
| 79% | 83% |
Strategy 3: Test and treat populations at higher risk for TB and LTBI
3.1 Immigrant/Refugee Evaluation Initiation within 30 Days
| 30%
| 37%
| 44%
| 51%
| 58%
|
3.2 Immigrant/Refugee Evaluation Completion within 120 Days
| 33% | 37% | 41% | 45% | 48% |
3.2a Immigrant/Refugee Evaluation Completion Ever | 54% | 59% | 65% | 70% | 75% |
3.3 Immigrant/Refugee LTBI Treatment Initiation | 73% | 75% | 77% | 79% | 81% |
3.4 Immigrant/Refugee LTBI Treatment Completion | 84% | 86% | 88% | 90% | 92% |
3.5 Persons in High Risk Group Tested for LTBI | TBD | TBD | TBD | TBD | TBD |
3.6 Persons in High Risk Group Completing LTBI Treatment | TBD | TBD | TBD | TBD | TBD |
Strategy 5: Surveillance
5.1 Data Reporting ā RVCT
| 99%
| 99%
| 99%
| 99%
| 99%
|
5.2 Universal Genotyping
| 96%
| 96% | 97%
| 97% | 98% |
5.3 Data Reportiāāng ā ARPE | 89%
| 89% | 89% | 89% | 89% |
5.4 Data Reporting ā EDN | 78% | 82% | 85% | 89%
| 93% |
Strategy 7: Laborāatory Strengthening
7.1 Laboratory Turnaround Time ā Culture | 52%
| 53%
| 54%
| 55%
| 55%
|
7.2 Laboratory Turnaround Time ā NAATāā | 89%
| 91% | 92% | 93% | 94% |
* Contacts to smear-positive TB; **Contacts to smear-positive or culture-positive TB
āARPE = Aggregate Reports on Performance Evaluation ā Contact Investigation
| āNAAT = nucleic acid amplification test
|
āEDN = Electronic Disease Notification system
| ā RVCT = Report of Verified Case of Tuberculosis
|
āHIV = human immunodeficiency virus
| ā TB = tuberculosis
|
āLTBI = latent tuberculosis infection ā
| ā US = United Statesā
|
ā